AZN vs. JAZZ: AstraZeneca vs. Jazz Pharmaceuticals Stock Comparison
How do AstraZeneca (AZN) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AstraZeneca (AZN) and Jazz Pharmaceuticals (JAZZ) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Jazz Pharmaceuticals (JAZZ) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AZN | JAZZ |
|---|---|---|
| Name | AstraZeneca PLC American Depositary Shares | Jazz Pharmaceuticals plc |
| Country/Region | United Kingdom | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 289.14 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 12, 1993 | June 1, 2007 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Total Return (1Y) | 12.64% | 84.44% |
| Total Return (3Y, Annualized) | 15.75% | 27.57% |
| Total Return (5Y, Annualized) | 10.63% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 28.21% | 38.74% |
| Beta (5Y) | 0.22 | 0.33 |
| Max Drawdown (5Y) | -27.87% | -42.03% |
| Avg. Volume (3M) | 3.14M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.30 | 2.07 |
| Sortino Ratio (1Y) | 0.44 | 4.14 |
Profitability
ROE (TTM)
AstraZeneca (AZN) at 22.57% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for AZN.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.57%
- Max
- 109.18%
- AZN
- 22.57%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
AstraZeneca (AZN) at 17.68% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.68%
- Max
- 18.05%
- AZN
- 17.68%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AstraZeneca (AZN) at 29.57% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.57%
- Max
- 83.12%
- AZN
- 29.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| ROE (TTM) | 22.57% | 5.05% |
| ROA (TTM) | 8.59% | 6.92% |
| Net Margin (TTM) | 17.68% | 4.37% |
| Operating Margin (TTM) | 29.57% | 30.17% |
| Gross Margin (TTM) | 81.78% | 91.10% |
Growth
Revenue Growth
Both AstraZeneca (AZN) at 8.63% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
AstraZeneca (AZN) at 45.33% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 4.88% |
| Revenue Growth (3Y CAGR) | 9.82% | 5.26% |
| EPS Growth (YoY) | 45.33% | -167.51% |
| EPS Growth (3Y CAGR) | 45.80% | -- |
Financial Strength
Current Ratio (MRQ)
Both AstraZeneca (AZN) at 1.01 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AZN
- 1.01
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Both AstraZeneca (AZN) at 0.66 and Jazz Pharmaceuticals (JAZZ) at 1.35 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.66
- Max
- 1.42
- AZN
- 0.66
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 1.82 |
| Debt / Equity (MRQ) | 0.66 | 1.35 |
| Net Debt / EBITDA | 1.23 | 1.39 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73%
- AZN
- 1.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.38%
- AZN
- 45.38%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.00% |
| Dividend Payout Ratio (TTM) | 45.38% | 0.00% |
Valuation
P/E Ratio (TTM)
AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.37
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- AZN
- 26.37
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AstraZeneca (AZN) at 4.63 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AZN
- 4.63
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both AstraZeneca (AZN) at 5.59 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.59
- Max
- 13.53
- Q3
- 6.54
- AZN
- 5.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AZN | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 26.37 | 69.46 |
| P/S Ratio (TTM) | 4.63 | 3.19 |
| P/B Ratio (MRQ) | 5.59 | 3.59 |
| Free Cash Flow Yield (TTM) | 1.95% | 11.16% |